Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
INCB000928 + ruxolitinib
- Development stage
- Phase 2
- Lead developer
- Incyte
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
**INCB000928 + ruxolitinib** is a combination investigational therapy being evaluated primarily for anemia due to myeloproliferative disorders, most notably myelofibrosis. INCB000928 (zilurgisertib) is a selective, oral activin receptor-like kinase 2 (ALK2) inhibitor, designed to lower elevated hepcidin and improve anemia pathology[5][8][9]. Ruxolitinib is an oral inhibitor of Janus kinase 1 (JAK1) and Janus kinase 2 (JAK2) that targets aberrant JAK-STAT signaling central to myeloproliferative neoplasms[2][5]. This combination may offer mechanistic synergy: ALK2 inhibition reduces hepcidin-driven anemia, while JAK1/2 inhibition by ruxolitinib ameliorates the underlying disease process.
- Other names
- INCB000928 + ruxolitinibzilurgisertib + ruxolitinibINCB00928 + ruxolitinib
02
Targets
ACVR1 (Activin receptor type I)JAK1 (Janus kinase 1)JAK2 (Janus kinase 2)JAK3 (Janus kinase 3)TYK2 (Tyrosine kinase 2)
Beyond the preview
Go deeper on INCB000928 + ruxolitinib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on INCB000928 + ruxolitinib.